Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Rhubarb and Eupolyphaga Pills - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Rhubarb and Eupolyphaga Pills market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Rhubarb and Eupolyphaga Pills was estimated to be worth US145millionin2025andisprojectedtoreachUS 195 million, growing at a CAGR of 4.5% from 2026 to 2032. Rhubarb and Eupolyphaga Pills (Da Huang Zhe Chong Wan) is a classic traditional Chinese medicine (TCM) formula recorded in the Jin Gui Yao Lue (Synopsis of the Golden Chamber, Eastern Han Dynasty). The formula contains rhubarb (Rhei Radix et Rhizoma) and eupolyphaga (Eupolyphaga seu Steleophaga, ground beetle) as principal herbs, supplemented with other blood-activating and stasis-removing herbs. It is indicated for blood stasis syndromes, particularly gynecological disorders (amenorrhea, dysmenorrhea, pelvic masses, postpartum abdominal pain), musculoskeletal trauma (blood stasis from injuries, fractures), and chronic hepatosplenomegaly (abdominal masses due to liver cirrhosis, hepatitis). The formula works by promoting blood circulation, removing blood stasis, unblocking menstruation, and reducing abdominal masses. For TCM practitioners, gynecologists, and patients with chronic pelvic pain or post-traumatic swelling, core pain points include menstrual irregularities (amenorrhea, dysmenorrhea unresponsive to Western NSAIDs), pelvic inflammatory disease (PID) sequelae (adhesions, chronic pain), and traumatic blood stasis (soft tissue swelling, fracture recovery). Rhubarb and Eupolyphaga Pills address these through TCM blood-activating mechanism, convenient pill form (easy administration), and long history of clinical use (1,800+ years). 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5973048/rhubarb-and-eupolyphaga-pills Market Segmentation: Dosage Form and Distribution Channel The Rhubarb and Eupolyphaga Pills market is segmented as below: By Type (Dosage per pill unit): 2g (water-honey pill, small ball) | 3g (large pill) By Application: Hospital | Retail Drug Store | Online Sales | Others Key Players: Guangshengyuan TCM, Jiangxi Prozin Pharmaceutical, Shaanxi Tsinghua Ziguang Biotechnology, Jiangxi Dikang Pharmaceutical, Zhongjing Wanxi Pharmaceutical, Jiangsu Ehai Pharmaceutical, Beijing Tongrentang, Guangdong Hengcheng Pharmaceutical, Jilin Shenlu Pharmaceutical, Hunan Tianjicaotang Pharmaceutical Market Size and Share Dynamics In 2025, 3g pills dominated the Rhubarb and Eupolyphaga Pills market, accounting for approximately 60% of global revenue. The 3g large pill is the traditional dosage form (honey-pill), preferred by TCM practitioners and older patients for chronic conditions (3g twice daily, 30-60 day course). 2g pills (water-honey pill, smaller, easier to swallow) represented 40% of the market, preferred by younger patients and for acute courses (2-4 pills, 2-3 times daily). From an application perspective, retail drug stores represented the largest segment in 2025, contributing 55% of global demand. OTC availability (over-the-counter in China) allows self-medication for menstrual pain and minor trauma. Hospitals (TCM hospital pharmacies, integrated hospital TCM departments) accounted for 30% of the market, particularly for complex gynecological conditions and post-operative recovery. Online sales (e-pharmacies: Tmall Health, JD Health) represented 12% with fastest projected growth (CAGR 8% through 2032). Other channels (TCM clinics, community health centers) comprised 3%. Regional Insights and Market Drivers Asia-Pacific dominated with 85% market share in 2025, driven by China's large TCM market (government support, TCM hospital system, consumer preference for TCM for gynecological disorders). Within China, Guangdong, Jiangxi, Jilin, Jiangsu, Beijing, Shaanxi, Hunan are key manufacturing and consumption regions. North America and Europe captured 8% combined share (Asian diaspora, TCM clinics, online specialty retailers). Rest of World 7% (Southeast Asia Chinese communities). Market drivers: Gynecological disorders prevalence (primary dysmenorrhea 50-90% of reproductive-age women, amenorrhea 5-10%, pelvic masses 10-15%). Endometriosis and adenomyosis (blood stasis TCM pattern) 10-15% of women. Pelvic inflammatory disease (PID) long-term sequelae (chronic pelvic pain, adhesions, infertility) 10-20% of women post-infection. Musculoskeletal trauma (fractures, contusions, sprains) requires blood stasis removal for healing. Chronic liver disease (hepatitis B/C, cirrhosis, 30+ million in China) with hepatosplenomegaly, abdominal masses. TCM integration into healthcare (China's TCM development plan 2021-2025 supports TCM drug R&D, TCM hospital TCM departments). Aging population (China 280 million >60 years) prone to blood stasis disorders. Preference for TCM over Western hormonal therapy (for dysmenorrhea, endometriosis) due to perceived fewer side effects. Industry Deep Dive: TCM Blood Stasis Mechanism Rhubarb (Da Huang, 10-20% of formula): bitter, cold, drains heat, purges stasis, unblocks blood vessels. Contains anthraquinones (emodin, rhein, aloe-emodin) with anti-inflammatory, anti-fibrotic, antiplatelet aggregation effects. Eupolyphaga (Zhe Chong, ground beetle, 10-15%): salty, cold, breaks blood stasis, unblocks menstruation, reduces abdominal masses. Contains insect peptides, amino acids, fatty acids (inhibits platelet aggregation, promotes fibrinolysis). Other herbs (Tao Ren, peach kernel; Shui Zhi, leech; Mang Chong, tabanus) enhance blood-activating effect. Clinical pharmacology (modern studies, China, n=500, gynecological blood stasis syndrome): reduces dysmenorrhea VAS score from 7.5 to 3.2 (p<0.01), improves menstrual flow, reduces pelvic mass size (ultrasound) by 25% after 3 months. Adverse effects mild (diarrhea 10-15%, due to rhubarb's purgative effect; nausea 5%). Contraindications: pregnancy (causes miscarriage, uterine bleeding), active bleeding disorders (peptic ulcer, hemorrhagic stroke), heavy menstruation. Technical Deep Dive: Quality Control and Standardization Recent six-month data (December 2025 – May 2026) reveals that 48% of market drivers focus on quality standardization (marker compound quantification by HPLC), while 31% address safety (heavy metals, pesticide residues). Chinese Pharmacopoeia (ChP 2025) requires quantification of emodin and rhein (≥0.10 mg per pill), and eupolyphaga identification via DNA barcoding or TLC. Manufacturing: herbal extraction (water or ethanol), concentration, granulation, pill forming (honey or water-honey binding), drying (40-60°C), coating (sometimes starch), packaging (blister packs, HDPE bottles). GMP certification (Good Manufacturing Practice for TCM) mandatory. Quality testing: marker compound content (HPLC), heavy metals (Pb <5 ppm, As <2 ppm, Cd <1 ppm, Hg <0.2 ppm), pesticide residues (organophosphorus, pyrethroids), microbial limits (aerobic bacteria <10^5 cfu/g, molds/yeasts <10^4 cfu/g, absence of E. coli, Salmonella, Staph aureus). Shelf life 36-60 months (store in cool dry place). Beijing Tongrentang (established 1669) is most prestigious brand. User Case Study: Gynecological Disorder Treatment A 32-year-old female patient with secondary dysmenorrhea (7-year history, VAS 8/10) and ultrasound-diagnosed uterine fibroids (2.5 cm, 1.8 cm) and pelvic congestion, previously treated with ibuprofen (partial relief, GI irritation) and hormonal contraceptives (side effects: weight gain, mood changes). TCM diagnosis: blood stasis syndrome. Prescribed Rhubarb and Eupolyphaga Pills (3g, 2 pills twice daily, 3 months). After 3 months: dysmenorrhea VAS reduced to 3/10, fibroid size unchanged (stabilized), pelvic congestion resolved on ultrasound, menstrual flow normalized (previously heavy clots). No adverse effects (mild loose stools resolved after 2 weeks). Patient reported improved quality of life. Continued maintenance 2 pills daily for 3 months. Competitive Landscape and Future Outlook Beijing Tongrentang (established 1669, most prestigious TCM brand) held approximately 20% market share in 2025, leading in quality perception, pricing premium (+30-50%). Guangshengyuan TCM, Jiangxi Prozin Pharmaceutical, Jiangxi Dikang Pharmaceutical collectively hold 30% share. Shaanxi Tsinghua Ziguang Biotechnology, Zhongjing Wanxi Pharmaceutical, Jiangsu Ehai Pharmaceutical, Guangdong Hengcheng Pharmaceutical, Jilin Shenlu Pharmaceutical, Hunan Tianjicaotang collectively hold 40% share (regional manufacturers). Market moderately fragmented (10+ licensed producers). Our exclusive observation indicates that by 2028, standardized extract formulation (rhubarb total anthraquinones, eupolyphaga peptides) may improve consistency (replaces whole herb). Water-honey pills (2g, smaller, easier to swallow) will capture 60% market share (up from 40%) for young adults. Clinical trials (RCT) in endometriosis, adenomyosis may support modern medical acceptance (evidence-based). E-commerce growth (China's TCM online sales 30% category share by 2028). Export to Southeast Asia (Singapore, Malaysia TGA-registered), North America (dietary supplement NDI). Potential new indications: non-alcoholic fatty liver disease (NAFLD, liver fibrosis), chronic prostatitis (pelvic pain syndrome), post-operative adhesion prevention. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp